Search results for: covid 19 testing

Project: EV3260 - COVID-19 Minigrants (Latinx) Ref. #: EV3260 - COVID-19 Minigrants (Latinx) Type: RFP Status: Open Open Date: Nov 17th 2023, 10:00 AM CST Questions Due Date: Never Contact Information: Kimberlee Hughes, kimberlee.hughes@kcmo.org Close Date: Dec 7th 2023, 11:30 PM CST Days Left: 4 Project Description:The COVID-19 pandemic followed the most common health trend in modern

Bid Details Planholder EV3260 - COVID-19 Minigrants (Latinx) Active Browse Awarded Bids Download Bid Package Bid Details Agency Name City of Kansas City, MO Bid Writer Kimberlee Hughes Bid ID RFP-EV3260 - COVID-19 Minigrants (Latinx)-0-2023/KH Bid Type RFP - Request For Proposals Broadcast Date 11/17/2023 10:00 AM Central Fiscal Year 2023 Due Date 12/07/2023 11:30 PM Central Bid Status Text The COVID-19 pandemic followed the most common health trend

Bid Details Planholder EV3260 - COVID-19 Minigrants (Latinx) Active Browse Awarded Bids Download Bid Package Bid Details Agency Name City of Kansas City, MO Bid Writer Kimberlee Hughes Bid ID RFP-EV3260 - COVID-19 Minigrants (Latinx)-0-2023/KH Bid Type RFP - Request For Proposals Broadcast Date 11/17/2023 10:00 AM Central Fiscal Year 2023 Due Date 12/07/2023 11:30 PM Central Bid Status Text The COVID-19 pandemic followed the most common health trend

COVID-19 pandemic followed the most common health trend in modern times - communities with lower levels of public health infrastructure suffered the most severe consequences.

COVID-19 pandemic followed the most common health trend in modern times - communities with lower levels of public health infrastructure suffered the most severe consequences.

For contractors working in Medium to High COVID-19 Community Levels testing will still be required to access DIA facilities until transmission levels are moved to Low. To facilitate this decision DIA is using the CDC COVID-19 Community Level by County’s website.

Deliverables: Rapid testing, under 25 minutes for result, for both SARS-CoV-2 and Influenza A/B testing concurrently as well as Influenza A/B and RSV testing concurrently, and FDA cleared to be utilized on an asymptomatic population. Rapid testing for SARS-CoV-2 >96% positive and negative agreement with both symptomatic and asymptomatic individuals.